IMUX – immunic, inc. (US:NASDAQ)
Stock Stats
News
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation [Yahoo! Finance]
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role [Yahoo! Finance]
Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Form DEF 14A IMMUNIC, INC. For: Jun 11
Form 8-K IMMUNIC, INC. For: Mar 04
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: HOWSON TAMAR D
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Nash Duane
Form 4 IMMUNIC, INC. For: Mar 04 Filed by: Vitt Daniel
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.